Inpatient management of iron deficiency anemia in pediatric patients with inflammatory bowel disease: A single center experience

• Published in: World journal of clinical pediatrics 2024-03, Vol.13 (1), p.89318-89318
• Main Authors: Manokaran, Krishanth, Spaan, Jonathan, Cataldo, Giulio, Lyons, Christopher, Mitchell, Paul D, Sare, Tatyana, Zimmerman, Lori A, Rufo, Paul A
• Format: Article
• Language: English
• Subjects: Observational Study
• ISSN: 2219-2808; 2219-2808
• DOI: 10.5409/wjcp.v13.i1.89318

Screening for iron deficiency anemia (IDA) is important in managing pediatric patients with inflammatory bowel disease (IBD). Concerns related to adverse reactions may contribute to a reluctance to prescribe intravenous (IV) iron to treat IDA in this population. To track the efficacy and safety of IV iron therapy in treating IDA in pediatric IBD patients admitted to our center. A longitudinal observational cohort study was performed on 236 consecutive pediatric patients admitted to our tertiary IBD care center between September 2017 and December 2019. 92 patients met study criteria for IDA, of which 57 received IV iron, 17 received oral iron, and 18 were discharged prior to receiving iron therapy. Patients treated with IV iron during their hospitalization experienced a significant increase of 1.9 (± 0.2) g/dL in mean (± SE) hemoglobin (Hb) concentration by the first ambulatory follow-up, compared to patients who received oral iron 0.8 (± 0.3) g/dL or no iron 0.8 (± 0.3) g/dL ( = 0.03). One out of 57 (1.8%) patients that received IV iron therapy experienced an adverse reaction. Our findings demonstrate that treatment with IV iron therapy is safe and efficacious in improving Hb and iron levels in pediatric patients with IDA and active IBD.